

CURRICULUM VITAE

PERSONAL DATA

Name: Stefan Stender
Mail: stefan.stender@regionh.dk
Birth date: 06-06-1979, Aarhus, Denmark

EDUCATION

2000-2007 MD, Aarhus University, Denmark
2009-2014 PhD, University of Copenhagen, Denmark (January 10th, 2014)
2014-2017 Postdoctoral research, University of Texas Southwestern, Dallas, Texas
2017-2021 Clinical specialization in clinical biochemistry (certified September 1st, 2021)

POSITIONS

2004-2005 Research student, Regenerative Medicine Institute, NUI Galway, Ireland
2007-2009 Resident, Hvidovre Hospital, Denmark
2009-2014 Research fellow, Dep. of Clinical Biochemistry, Rigshospitalet, Copenhagen
2014-2017 Post-doctoral fellow in the lab of Helen Hobbs and Jonathan Cohen, Dep. of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, Texas.
2017-2021 MD, Dep. of Clinical Biochemistry, Rigshospitalet and Bispebjerg & Frederiksberg Hospital, and Gastroenterology, Hvidovre Hospital.
2021- MD, Dep. of Clinical Biochemistry, Rigshospitalet.
2023- Clinical Research Associate Professor, University of Copenhagen

SCIENTIFIC AWARDS & HONORS

2013 Boserup-Prisen (DKK 75.000)
2015 Sapere Aude Research Talent, Independent Research Fund Denmark
2018 Astrup Prize (1st prize, DKK 60.000)
2019 Sapere Aude Research Leader, Independent Research Fund Denmark
2022 Borregaard Clinical Ascending Investigator, Novo Nordisk Foundation

SCIENTIFIC FOCUS AREAS

I study the genetic risk of common complex disorders in humans, with a focus on cardiovascular and gastrointestinal diseases. My studies contributed to the discovery and characterization of several genetic factors that promote or protect from fatty liver disease, including *TM6SF2* and *HSD17B13*. I have also investigated the genetic basis of gallstones and ischemic heart disease. During my studies, I have employed a wide spectrum of methods, ranging from large-scale genetic association studies in population-based cohorts, to exome sequencing of patients, to functional studies in cells and mice.

BIBLIOMETRY

37 original articles (15 as first author, 6 as last author).
Number of articles published in journals with impact factor >20: 11 (hereof 5 as first author).
Number of articles published in journals with impact factor 10 to 20: 8 (3 as first, 3 as last author)
H-index (Google Scholar, July 2023): 26, Total number of citations (Google Scholar): 4614

GRANTS

2010	Boserupfonden	DKK 0.2M
2010	Research Fund at Rigshospitalet, PhD-grant	DKK 1.7M
2014	DFF, post-doc grant	DKK 1.8M
2015	DFF: Sapere Aude Research Talent	DKK 0.5M
2019	DFF: Sapere Aude Research Leader	DKK 4.3M
2022	NNF: Borregaard Clinical Ascending Investigator	DKK 8.3M
2022	Lægeforeningens Forskningsfond	DKK 0.15M

2010-2022 Multiple smaller grants totaling DKK ~1M

SUPERVISION

2012 - 2016 Bo Kobberv Lauridsen, MD: PhD project-supervisor.
2017 - now Helene Gellert-Kristensen, MD: Candidate thesis and PhD project-supervisor.
2018 - now Anne-Sofie Seidelin, MD: Candidate thesis and PhD project-supervisor.
2019 - now Josephine Grandt, MSc: PhD co-supervisor.
2020 - now Elias Badal Rashu, MD: PhD project-supervisor.
2022 - now Tim Eyrich, MSc: Candidate thesis supervisor (from 2023: research assistant supervisor).

INVITED TALKS

2018 Wallenberg lab, Gothenburg University
2018 Bristol University, MRC Integrative Epidemiology Unit
2019 × 2 University of Copenhagen, Department of Biomedical Sciences and CPR
2023 University of Texas Southwestern, Dallas
2023 Danish Society for Young Gastroenterologists annual meeting

EDITOR

2022 - now On the editorial board of Diabetes Research Reviews and Metabolism

REVIEWER

Grants: Independent Research Fund Denmark, Diabetes UK, Croatian Science Foundation.
Journals: Recurrent reviewer for >30 different journals, including JAMA, BMJ, JACC, EHJ, Gastroenterology, Hepatology, Nat Comm, J Hepatology, Lancet Gastroenterology & Hepatology, Clinical Gastroenterology & Hepatology, Diabetes Care, Diabetologia, Am J Gastroenterology, Diabetes, IJE.
PhDs: Mie Balling, University of Copenhagen (2023); opponent
Malene Revsbech Christiansen, University of Copenhagen (2023); opponent

COMMITTEE WORK

2013/18/23 Scientific Chairman, SSAR Annual Meeting, Humlebæk, Denmark
2023 Session chairman, DSKB annual meeting, Esbjerg, Denmark

TEACHING

2011-2014 Lectures in clinical biochemistry for 3rd year MD students, University of Copenhagen.
2020 Lecture on fatty liver disease, MOOC, University of Copenhagen.
2020-now Biannual 3×45 min lectures for PhD-course 'Omics for clinical researchers', University of Copenhagen.
2022 Lecture about genetics, as part of course for MDs specializing in clinical biochemistry.
2022 Lecture about the use of R for MDs specializing in clinical biochemistry.

INTERNATIONAL RELATIONSHIPS

I collaborate with Director George Davey-Smith and Senior Researcher Tom Richardson from the MRC Integrative Epidemiology Unit at University of Bristol, on genetic studies in the UK Biobank. I visited their department for 1 month in 2019. Moreover, I collaborate with Regeneron Genetics Center (New York), on genetics of common diseases, and with leading European researchers in the field of fatty liver disease genetics.

LEADERSHIP EXPERIENCE

Since returning to Denmark in 2017, I have led my own research and started to build a small group. So far, we have published 6 papers with me as last/corresponding author.

MEDIA APPEARANCES AND MENTIONS

2014 Post doctoral studies featured on Videnskab.dk, eb.dk among other Danish media.

2017	Stender et al, Nat Gen 2017 selected as 'Editor's choice' in Science.
2017	Stender et al, Nat Gen 2017 featured in Jyllands-Posten.
2020	Gallstone/coffee paper (2 nd authored) in international media (NYT, The Guardian)
2022	Invited guest in 'Sygt Nok', radio program on DR P1 (1 hour discussion)

PUBLICATION LIST

I. ORIGINAL SCIENTIFIC PUBLICATIONS (PEER REVIEWED)

1. **Stender S**, Murphy M, O'Brien T, Stengaard C, Ulrich-Vinther M, Søballe K, Barry F. Adeno-associated viral vector transduction of human mesenchymal stem cells. *Eur Cell Mater* 2007;13:93-9.
2. **Stender S**, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A. Sterol transporter adenosine triphosphate-binding cassette transporter G8, gallstones, and biliary cancer in 62,000 individuals from the general population. *Hepatology*. 2011;53:640-8.
3. Benn M, Tybjærg-Hansen A, **Stender S**, Frikke-Schmidt R, Nordestgaard BG. LDL cholesterol and risk of cancer: Mendelian randomization on 67,000 individuals from the general population. *J Natl Cancer Inst*. 2011;103:508-519.
4. **Stender S**, Frikke-Schmidt R, Anestis A, Kardassis D, Sethi AA, Nordestgaard BG, Tybjærg-Hansen A. Genetic variation in liver X receptor alpha and risk of ischemic vascular disease in the general population. *Arterioscler Thromb Vasc Biol*. 2011;31:2990-6.
5. Smith AJP, Howard P, Shah S, Eriksson P, **Stender S**, Giambartolomei C, Folkersen L, Tybjærg-Hansen A, Kumari M, Palmen J, Hingorani AD, Talmud PJ, Humphries SE. Use of Allele-Specific FAIRE to Determine Functional Regulatory Polymorphism using Large-Scale Genotyping Arrays. *PLOS Genet*. 2012;8:e1002908.
6. **Stender S**, Frikke-Schmidt R, Nordestgaard BG, Grande P, Tybjærg-Hansen A. Genetically elevated bilirubin and risk of ischaemic heart disease: three Mendelian randomization studies and a meta-analysis. *J Intern Med*. 2013;273:59-68.
7. **Stender S**, Frikke-Schmidt R, Benn M, Nordestgaard BG, Tybjærg-Hansen A. Low density lipoprotein cholesterol and risk of gallstone disease: a Mendelian randomization study and meta-analyses. *J Hepatol*. 2013;58:126-33.
8. **Stender S**, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A. Extreme bilirubin levels as a causal risk factor for symptomatic gallstone disease. *JAMA Int Med*. 2013;173:1222-8.
9. **Stender S**, Nordestgaard BG, Tybjærg-Hansen A. Genetically elevated body mass index as a causal risk factor for symptomatic gallstone disease: a Mendelian randomization study. *Hepatology*. 2013;58:2133-41.
10. Kozlitina J, Smagris E, **Stender S**, Nordestgaard BG, Zhou HH, Tybjærg-Hansen A, Vogt TF, Hobbs HH, Cohen JC. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. *Nat Genet*. 2014;46:352-6.
11. **Stender S**, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A. The ABCG5/8 cholesterol transporter and myocardial infarction versus gallstone disease. *J Am Coll Cardiol*. 2014;63:2121-2128.

12. Lauridsen BK, **Stender S**, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Genetic variation in the cholesterol transporter NPC1L1, ischaemic vascular disease, and gallstone disease. *Eur Heart J*. 2015;36:1601-8.
13. Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JE, Shah T, Sofat R, **Stender S**, Johnson PC, Scott RA, Leusink M, Verweij N, Sharp SJ, Guo Y, Giambartolomei C, Chung C, Peasey A, Amuzu A, Li K, Palmen J, Howard P, Cooper JA, Drenos F, Li YR, Lowe G, Gallacher J, Stewart MC, Tzoulaki I, Buxbaum SG, van der A DL, Forouhi NG, Onland-Moret NC, van der Schouw YT, Schnabel RB, Hubacek JA, Kubinova R, Baceviciene M, Tamosiunas A, Pajak A, Topor-Madry R, Stepaniak U, Malyutina S, Baldassarre D, Sennblad B, Tremoli E, de Faire U, Veglia F, Ford I, Jukema JW, Westendorp RG, de Borst GJ, de Jong PA, Algra A, Spiering W, Maitland-van der Zee AH, Klungel OH, de Boer A, Doevendans PA, Eaton CB, Robinson JG, Duggan D; DIAGRAM Consortium; MAGIC Consortium; InterAct Consortium, Kjekshus J, Downs JR, Gotto AM, Keech AC, Marchioli R, Tognoni G, Sever PS, Poulter NR, Waters DD, Pedersen TR, Amarenco P, Nakamura H, McMurray JJ, Lewsey JD, Chasman DI, Ridker PM, Maggioni AP, Tavazzi L, Ray KK, Seshasai SR, Manson JE, Price JF, Whincup PH, Morris RW, Lawlor DA, Smith GD, Ben-Shlomo Y, Schreiner PJ, Fornage M, Siscovick DS, Cushman M, Kumari M, Wareham NJ, Verschuren WM, Redline S, Patel SR, Whittaker JC, Hamsten A, Delaney JA, Dale C, Gaunt TR, Wong A, Kuh D, Hardy R, Kathiresan S, Castillo BA, van der Harst P, Brunner EJ, Tybjaerg-Hansen A, Marmot MG, Krauss RM, Tsai M, Coresh J, Hoogeveen RC, Psaty BM, Lange LA, Hakonarson H, Dudbridge F, Humphries SE, Talmud PJ, Kivimäki M, Timpson NJ, Langenberg C, Asselbergs FW, Voevoda M, Bobak M, Pikhart H, Wilson JG, Reiner AP, Keating BJ, Hingorani AD, Sattar N. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. *Lancet*. 2015;385:351-61.
14. **Stender S**, Chakrabarti RS, Xing C, Gotway G, Cohen JC, Hobbs HH. Adult-onset liver disease and hepatocellular carcinoma in S-adenosylhomocysteine hydrolase deficiency. *Mol Gen Metab*. 2015;116: 269-74.
15. Joshi AD*, Andersson C*, Buch S*, **Stender S***, Noordam R*, Chen W*, Weeke PE*, Auer PL, Boehm B, Chen C, Choi H, Curhan G, Denny JC, De Vivo I, Eicher JD, Ellinghaus D, Folsom AR, Fuchs C, Gala M, Haessler J, Hofman A, Hu F, Hunter DJ, Janssen HL, Kang JH, Kooperberg C, Kraft P, Kratzer W, Lieb W, Lutsey PL, Darwish Murad S, Nordestgaard BG, Pasquale LR, Reiner AP, Ridker PM, Rimm E, Rose LM, Shaffer CM, Schafmayer C, Tamimi RM, Uitterlinden AG, Völker U, Völzke H, Wakabayashi Y, Wiggs JL, Zhu J, Roden DM, Stricker BH, Tang W, Teumer A, Hampe J, Tybjaerg-Hansen A, Chasman DI, Chan AT, Johnson AD. Four Susceptibility Loci for Gallstone Disease Identified in a Meta-analysis of Genome-wide Association Studies. *Gastroenterology*. 2016;151:351-363. ***Shared first-authorship.**
16. **Stender S**, Kozlitina J, Tybjaerg-Hansen A, Nordestgaard BG, Hobbs HH, Cohen JC. Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci. *Nat Genet*. 2017;49:842-847.
17. Lauridsen BK, **Stender S**, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Using genetics to explore whether the cholesterol-lowering drug ezetimibe may cause an increased risk of cancer. *Int J Epidemiol*. 2017;46:1777-85.

18. Lauridsen BK, **Stender S**, Kristensen TH, Kofoed KF, Køber L, Nordestgaard BG, Tybjaerg-Hansen A. Liver fat content, NAFLD, and ischemic heart disease: Mendelian randomization and meta-analysis of 279,013 individuals. *Eur Heart J*. 2018;39:385-393.
19. Dongiovanni P*, **Stender S***, Pietrelli A*, Mancina RM*, Cespiati A, Petta S, Pelusi S, Pingitore P, , Badiali S, Maggioni M, Mannisto V, Grimaudo S, Pipitone RM, Pihlajamaki J, Craxi A, Taube M, Carlsson L, Fargion S, Romeo S, Kozlitina J, Valenti L. Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. *J Intern Med*. 2018;283:356-370. ***Shared first-authorship.**
20. **Stender S**, Smagris E, Lauridsen BK, Kofoed KF, Nordestgaard BG, Tybjaerg-Hansen A, Pennacchio LA, Dickel DE, Cohen JC, Hobbs HH. Relationship between Genetic Variation at PPP1R3B and Liver Glycogen and Triglyceride Levels. *Hepatology*. 2018;67:2182-2195.
21. Abul-Husn NS, Cheng X, Li AH, Xin Y, Schurmann C, Stevis P, Liu Y, Kozlitina J, **Stender S**, Wood GC, Stepanchick AN, Still MD, McCarthy S, O'Dushlaine C, Packer JS, Balasubramanian S, Gosalia N, Esopi D, Kim SY, Mukherjee S, Lopez AE, Fuller ED, Penn J, Chu X, Luo JZ, Mirshahi UL, Carey DJ, on behalf of the Geisinger-Regeneron DiscovEHR Collaboration, Still CD, Feldman MD, Small A, Damrauer SM, Rader DJ, Zambrowicz B, Olson W, Murphy AJ, Borecki IB, Shuldiner AR, Reid JG, Overton JD, Yancopoulos GD, Hobbs HH, Cohen JC, Gottesman O, Teslovich TM, Baras A, Mirshahi T, Gromada J, Dewey FE. A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease. *N Engl J Med*. 2018;378:1096-1106.
22. Gellert-Kristensen H, Dalila N, Nielsen SF, Nordestgaard BG, Tybjaerg-Hansen A, **Stender S**. Identification and replication of six loci associated with gallstone disease. *Hepatology* 2019;70:597-609.
23. Gellert-Kristensen H, Nordestgaard BG, Tybjaerg-Hansen A, **Stender S**. High risk of fatty liver disease amplifies the alanine transaminase-lowering effect of a HSD17B13 variant. *Hepatology*. 2020;71:56-66.
24. Nordestgaard AT, **Stender S**, Nordestgaard BG, Tybjaerg-Hansen A. Coffee intake protects against symptomatic gallstone disease in the general population: a Mendelian randomization study. *J Intern Med*, 2020;287:42-53.
25. Johansen MJ, Gade J, **Stender S**, Frithioff-Bøjsøe C, Lund MV, Chabanova E, Thomsen HS, Pedersen O, Fonvig CE, Hansen T, Holm JC. The effect of overweight and obesity on liver biochemical markers in children and adolescents. *J Clin Endocrinol Metab*. 2020;105:dgz010.
26. **Stender S***, Zaha VG*, Malloy CR, Suderth J, DeBaradinis R, Park JM. Assessment of rapid hepatic glycogen synthesis in humans using dynamic ¹³C MR spectroscopy. *Hepatol Commun*. 2020;4:425-433. ***Shared first-authorship.**
27. Gellert-Kristensen H, Richardson TG, Davey Smith G, Nordestgaard BG, Tybjaerg-Hansen A, **Stender S**. Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population. *Hepatology*. 2020;72:845-856.

28. Seidelin AS, Nordestgaard BG, Tybjaerg-Hansen A, **Stender S**. Genetic Variation at *PPP1R3B* Increases Hepatic CT Attenuation and Interacts with Prandial Status on Plasma Glucose. *J Clin Endocrinol Metab*. 2020;105:dga151.
29. Kirkegaard-Klitbo DM, Fuchs A, **Stender S**, Sigvardsen PE, Kühl JT, Kofoed KF, Køber L, Nordestgaard BG, Bendtsen F, Mocroft A, Lundgren J, Nielsen SD, Benfield T. Prevalence and Risk Factors of Moderate to Severe Hepatic Steatosis in HIV Infection: The Copenhagen Co-Morbidity Liver Study. *J Infect Dis*. 2020;222:1353-1362.
30. Israelsen M, Juel HB, Detlefsen S, Madsen BS, Rasmussen DN, Larsen TR, Kjærgaard M, Jensen MF, **Stender S**, Hansen T, Krag A, Thiele M. Metabolic and genetic risk factors are the strongest predictors of severity of alcohol-related liver fibrosis. *Clin Gastroenterol Hepatol*. 2020:S1542-3565(20)31628-1.
31. Teo K, Abeysekera KWM, Adams L, Aigner E, Anstee QM, Banales JM, Banerjee R, Basu P, Berg T, Bhatnagar P, Buch S, Canbay A, Caprio S, Chatterjee A, Chen YI, Chowdhury A, Daly AK, Datz C, de Gracia Hahn D, DiStefano JK, Dong J, Duret A, EU-PNAFLD Investigators, Emdin C, Fairey M, Gerhard GS, GOLD Consortium, Guo X, Hampe J, Hickman M, Heintz L, Hudert C, Hunter H, Kelly M, Kozlitina J, Krawczyk M, Lammert F, Langenberg C, Lavine J, Li L, Lim HK, Loomba R, Luukkonen PK, Melton PE, Mori TA, Palmer ND, Parisinos CA, Pillai SG, Qayyum F, Reichert MC, Romeo S, Rotter JI, Im YR, Santoro N, Schafmayer C, Speliotes EK, **Stender S**, Stickel F, Still CD, Strnad P, Taylor KD, Tybjaerg-Hansen A, Umano GR, Utukuri M, Valenti L, Wagenknecht LE, Wareham NJ, Watanabe RM, Wattacheril J, Yaghootkar H, Yki-Järvinen H, Young KA, Mann JP. rs641738C> T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis. *J Hepatol*. 2021;74:20-30.
32. Seidelin AS, Nordestgaard BG, Tybjaerg-Hansen A, Yaghootkar H, **Stender S**. A rare genetic variant in the manganese transporter SLC30A10 and elevated liver enzymes in the general population. *Hepatol Int*. 2022;16:702-711.
33. Fred RG, Pedersen JS, Thompson JJ, Lee J, Timshel PN, **Stender S**, Rygg MO, Gluud LL, Kristiansen VB, Bendtsen F, Hansen T, Pers TH. Single-cell transcriptome and cell type-specific molecular pathways of human non-alcoholic steatohepatitis. *Sci Rep* 2022; 12, 1-13.
34. Praveen K, Patel GC, Gurski L, Ayer AH, Persaud T, Still MD, Miloscio L, Van Zyl T, Di Gioia SA, Brumpton B, Krebs K, Åsvold BO, Chen E, Chavali VRM, Fury W, Gudiseva HV, Hyde S, Jorgenson E, Lefebvre S, Li D, Li A, McIninch J, Patel B, Rabinowitz JS, Salowe R, Schurmann C, Seidelin AS, Stahl E, Sun D, Teslovich TM, Tybjaerg-Hansen A, Willer C, Waldron S, Walley S, Yang H, Zaveri S; Regeneron Genetics Center; GHS-RGC DiscovEHR Collaboration; Estonian Biobank Research Team, Hu Y, Hveem K, Melander O, Milani L, **Stender S**, O'Brien JM, Jones MB, Abecasis GR, Cantor MN, Weyne J, Karalis K, Economides A, Della Gatta G, Ferreira MA, Yancopoulos GD, Baras A, Romano C, Coppola G. *ANGPTL7*, a therapeutic target for increased intraocular pressure and glaucoma. *Commun Biol*. 2022;5:1051.
35. **Stender S***, Davey Smith G, Richardson TG. Genetic variation and elevated liver enzymes during childhood, adolescence and early adulthood. *Int J Epidemiol*. 2023; Apr 27:dyad048.

***Corresponding author.**

36. Huang Y, Stinson SE, Juel HB, Lund MAV, Holm LA, Fonvig CE, Nielsen T, Grarup N, Pedersen O, Christiansen M, Chabanova E, Thomsen HS, Krag A, **Stender S**, Holm JC, Hansen T. An adult-based genetic risk score for liver fat associates with liver and plasma lipid traits in children and adolescents. *Liver Int.* 2023 doi: 10.1111/liv.15613.
37. Gellert-Kristensen H, Tybjærg-Hansen A, Nordestgaard BG, Ghouse J, Fuchs A, Kühl JT, Sigvardsen PE, Kofoed KF, **Stender S**. Genetic risk of fatty liver disease and mortality in the general population: a Mendelian randomization study. *Liver Int.* 2023. doi: 10.1111/liv.15629.

II. SCIENTIFIC REVIEWS (PEER REVIEWED)

1. **Stender S**, Tybjærg-Hansen A. Using human genetics to predict the effects and side effects of drugs. *Curr Opin Lipidol.* 2016; 27:105-11.

III. OTHER PEER REVIEWED PUBLICATIONS (parallel publications, editorials, letters etc.)

1. Cohen JC, **Stender S**, Hobbs HH. APOC3, coronary disease, and complexities of Mendelian randomization. *Cell Metab.* 2014;20:387-9. [commentary]
2. Lauridsen BK, **Stender S**, Tybjærg-Hansen. Genetic variation in NPC1L1 and risk of gallstone disease. *J Am Coll Cardiol.* 2015;66:1086. [letter]
3. Kozlitina J, **Stender S**, Hobbs HH, Cohen JC. HSD17B13 and Chronic Liver Disease in Blacks and Hispanics. *N Engl J Med.* 2018;379:1876-1877. [letter]
4. **Stender S**, Loomba R. PNPLA3 genotype and risk of liver and all-cause mortality. *Hepatology.* 2020;71:777-779. [editorial]
5. **Stender S**, Romeo S. HSD17B13 as a promising therapeutic target against chronic liver disease. *Liver Int.* 2020;40:756-757. [editorial]

IV. BOOK CHAPTERS AND BOOKS

1. **Stender S**, Grarup N, Hansen T. Genetic Aspects of Non-Alcoholic Fatty Liver Disease (NAFLD). *Springer 2019. The Human Gut-Liver-Axis in Health and Disease.* 195-206.

V. NON-SCIENTIFIC AND POPULAR PUBLICATIONS

1. **Stender S**. Biotin-interferens af laboratorie-analyser. *Klinisk Biokemi i Norden.* 2018;4:32-34.
2. **Stender S**. Overvågning af intern kvalitetskontrol ved hjælp af R-program. *DSKB-nyt.* 2021;2: 24-25.